Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intra-tumor Drug-eluting Microspheres in Advanced Solid Tumors
NCT04770207Phase 2Recruiting
- Sponsor
- Second Affiliated Hospital of Guangzhou Medical University
- Start
- Nov 2020
- Primary completion
- Nov 2029
- Modality
- Antibody Conjugates, DNA Intercalators/Alkylators, Cytokines & Interferons
- Countries
- 1
01
Overview
A Phase 2 trial of pembrolizumab, durvalumab, ipilimumab, doxorubicin, idarubicin in solid tumor, hepatocellular carcinoma (HCC), sponsored by Second Affiliated Hospital of Guangzhou Medical University. Started Nov 2020; status: recruiting.
02
Drugs
03
Conditions
solid tumorhepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT04770207.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04770207.